{
    "clinical_study": {
        "@rank": "112793", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose V404 PDS", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High Dose V404 PDS", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is intended to evaluate the safety of V404 PDS in patients with chronic\n      non-infectious uveitis. Secondarily, the study will evaluate whether V404 PDS can provide\n      clinically measurable benefit over an extended period of time in patients with chronic\n      non-infectious uveitis."
        }, 
        "brief_title": "Safety and Preliminary Efficacy Study of V404 PDS in Uveitis", 
        "condition": [
            "Uveitis, Posterior", 
            "Uveitis, Intermediate"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Uveitis", 
                "Chorioretinitis", 
                "Uveitis, Intermediate", 
                "Uveitis, Posterior"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older\n\n          -  Confirmed diagnosis of active uveitis\n\n          -  Sufficient lens/media clarity\n\n          -  Meet best-corrected visual acuity criteria\n\n          -  Willing and able to use contraception\n\n        Exclusion Criteria:\n\n          -  Pregnant, breast feeding\n\n          -  Uncontrolled glaucoma\n\n          -  Intraocular surgery or periocular/intraocular injections within 6 weeks\n\n          -  Periocular or intraocular steroid within 3 months\n\n          -  Prior vitrectomy\n\n          -  Prior corneal transplant\n\n          -  Prior fluocinolone implant\n\n          -  Allergy or sensitivity to study drug\n\n          -  Participation in other trial within 30 days\n\n          -  Abnormal liver function\n\n          -  History of positive serum tuberculosis test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125266", 
            "org_study_id": "V4041"
        }, 
        "intervention": {
            "arm_group_label": [
                "Low Dose V404 PDS", 
                "High Dose V404 PDS"
            ], 
            "description": "Sustained Release", 
            "intervention_name": "V404", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Golden", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis", 
        "other_outcome": {
            "measure": "Change in macular thickness by ocular coherence tomography", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 Months"
        }, 
        "overall_contact": {
            "email": "serickson@fsv4.com", 
            "last_name": "Signe Erickson, PhD", 
            "phone": "650-223-8103"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125266"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in vitreous haze score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 Months"
        }, 
        "source": "Forsight Vision4", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Forsight Vision4", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}